Overview

A Study of PARG Inhibitor XNW29016 in Patients With Advanced Solid Tumors Who Failed Standard Treatment

Status:
RECRUITING
Trial end date:
2027-08-16
Target enrollment:
Participant gender:
Summary
The purpose of this study is to characterize the safety, tolerability, and efficacy of XNW29016 in participants with advanced solid tumors .
Phase:
PHASE1
Details
Lead Sponsor:
Evopoint Biosciences Inc.
Collaborator:
Cancer Institute and Hospital, Chinese Academy of Medical Sciences